AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give AbCellera an average rating of "Moderate Buy" across six firms (1 sell, 1 hold, 3 buy, 1 strong buy) with a consensus 12‑month price target of $8.40.
• In its latest quarter AbCellera beat estimates, reporting EPS of ($0.03) vs. consensus ($0.18) and revenue of $44.85M vs. $6.31M, though the company remains unprofitable with a -198% net margin.
• Shares opened at $4.43, trade within a 52‑week range of $1.94–$6.51, have a market cap of $1.35B, and about 61.4% of the stock is institutionally owned.

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.40.

Several research analysts recently issued reports on ABCL shares. Weiss Ratings reissued a "sell (d-)" rating on shares of AbCellera Biologics in a research note on Monday, April 20th. JonesTrading started coverage on shares of AbCellera Biologics in a research note on Friday, April 10th. They set a "buy" rating and a $11.00 target price on the stock. Finally, Wall Street Zen raised shares of AbCellera Biologics from a "sell" rating to a "hold" rating in a research note on Saturday, February 14th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hollencrest Capital Management bought a new position in AbCellera Biologics during the third quarter worth $25,000. AssuredPartners Investment Advisors LLC bought a new position in AbCellera Biologics during the fourth quarter worth $34,000. OneDigital Investment Advisors LLC bought a new position in AbCellera Biologics during the third quarter worth $52,000. Insigneo Advisory Services LLC bought a new position in AbCellera Biologics during the third quarter worth $52,000. Finally, Voleon Capital Management LP bought a new position in AbCellera Biologics during the third quarter worth $56,000. 61.42% of the stock is owned by institutional investors.

AbCellera Biologics Stock Performance

NASDAQ:ABCL opened at $4.43 on Monday. The firm's fifty day moving average is $3.60 and its 200-day moving average is $3.86. AbCellera Biologics has a 52 week low of $1.94 and a 52 week high of $6.51. The firm has a market cap of $1.35 billion, a P/E ratio of -9.04 and a beta of 1.02.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.15. The company had revenue of $44.85 million for the quarter, compared to analyst estimates of $6.31 million. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. As a group, sell-side analysts anticipate that AbCellera Biologics will post -0.89 earnings per share for the current year.

About AbCellera Biologics

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.